Navigation Links
Drug Combo Might Fight Aggressive Breast Cancer More Safely
Date:10/6/2011

ion leads to excess production of HER2 in the cancer cells.

The researchers evaluated disease-free survival and overall survival at five years. The addition of the one year of Herceptin improved both disease-free and overall survival. The disease-free survival rates at five years were 75 percent in the ACT group, 84 percent in the ACTH group and 81 percent in the TCH group.

Overall survival was 87 percent for the ACT group, 92 percent for the ACTH and 91 percent in the TCH group.

However, the rates of congestive heart failure and other cardiac problems were higher in the ACTH group than in the TCH group. Twenty-one of those on ACTH had congestive heart failure, compared with four in the TCH group.

There were fewer reports of side effects such as joint pain and vomiting with the TCH group compared with the ACTH group, Slamon found. "And you get comparable effects," he noted.

Sanofi-Aventis and Genentech (which makes Herceptin) funded the study; Slamon reports receiving honoraria and reimbursement for travel expenses from both companies.

The latest report echoes findings from several previous ones, Slamon said. Doctors have been using the TCH regimen in women at risk for cardiac problems; it is approved by the U.S. Food and Drug Administration. "We're saying it should be used for everybody," Slamon said. "We are saying we think it is the standard of care, with comparable effects, and you lose all the anthracycline toxicity."

However, Dr. Daniel F. Hayes, clinical director of the breast oncology program at the University of Michigan Comprehensive Cancer Center in Ann Arbor, disagreed.

"I think TCH is a standard of care, it's not the standard of care," he said.

"Herceptin itself can cause heart failure," Hayes said. In the study, there were fewer cases of it in those who got Herceptin without anthracyclines, but it did still occur.

He suggests a risk-adapted approach, in which a doctor would decide which
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. For Some Prostate Cancer Patients, Combo Treatment Improves Survival
2. New Combo Therapy May Prevent TB, Save Lives in People With HIV
3. Vitamin D, Calcium Combo May Halve Melanoma Risk in Some Women
4. Energy Drink-Vodka Combo Nearly Kills Teen
5. Daily Four-Drug Combo Pill Halves Heart Disease Risk: Study
6. Combo of Paxil, Pravachol May Raise Blood Sugar
7. Chemo Combo May Help Stave Off Pancreatic Cancer Death
8. Alcohol-Energy Drink Combo Riskier Than Booze Alone, Study Says
9. Low-Intensity Exercise, Drug Combo Can Help Parkinsons Patients, Studies Show
10. Diet-Exercise Combo Seems to Work Best for Obese Seniors
11. Risks May Outweigh Benefits for Blood Pressure Drug Combo
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Combo Might Fight Aggressive Breast Cancer More Safely
(Date:10/1/2014)... October 01, 2014 October is national ... and early detection plans while raising money for breast ... Breast Cancer Awareness Month in the effort to ... to promote the importance of having access to clean, ... may be linked to certain forms of cancer. ...
(Date:10/1/2014)... Two bicyclists began a journey on September 8, ... an effort to raise funds and awareness to the ... father-daughter team, plan to bike more than 4,000 miles ... in Key West Florida. Funds raised along their ... nonprofit organization that assists post-9/11 service members, their families, ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 This October, ... to consumer lab testing, is offering 10% off all ... DIBN10 when placing their order to save. The Center ... the United States are affected by Diabetes. Because many ... to go undiagnosed until it causes serious health problems. ...
(Date:10/1/2014)... The Oliver Law Group P.C. ... Other-Sonic Ultrasound Gel lawsuit web page to ... surrounding the 2011 Pseudomonas aeruginosa / bacterial infection ... Michigan, which was ultimately traced to the recalled ... Beaumont patients who allegedly became ill following exposure ...
(Date:10/1/2014)... The annual Social Security cost-of-living adjustment (COLA) ... a new forecast by The Senior Citizens League (TSCL) ... (CPI) data through August, TSCL forecasts that COLAs will be ... consecutive year of record low COLAs,” states TSCL Chairman, Ed ... in 1975,” he notes. , Over the past five years ...
Breaking Medicine News(10 mins):Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2Health News:Request A Test Offers 10% off Diabetes Testing in October 2014 2Health News:Request A Test Offers 10% off Diabetes Testing in October 2014 3Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 2Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 3Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 4Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 2Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 3
... Today, Functionalab, a revolutionary new line of health and ... Bendel on 5th Avenue in New York City. ... in partnership with a globally recognized developer of science-based ... quality, potency and effectiveness. , , ...
... Misonix, Inc. (Nasdaq: MSON ), a developer of ... used for the ablation of tumors and worldwide for other ... and nine months ended March 31, 2009. Michael A. ... Senior VP and Chief Financial Officer, will host a conference ...
... increase patient access to stroke specialists, especially in rural ... (TIA), once known as a "mini" or "warning" stroke, ... full-blown stroke, according to two separate scientific statements and ... of the American Heart Association . , Telemedicine ...
... Inc. (OTC Bulletin Board: DSCI), a provider of ... quarter 2009 results before market on Monday, May 18, 2009. ... day to discuss the results at 11:00 am EDT. Interested ... 98098954 to access the call. You may also access this ...
... option maximizes UHPLC or HPLC productivity via seamless ... all new and existing Corona detector customersCHELMSFORD, Mass., ... UHPLC detector with a Waters ACQUITY UPLC(R) ... a new Empower 2/Corona detector instrument-control software driver. ...
... Co., Inc., (NYSE Amex: TPI ), a ... in Chengdu, China, today,announced that management will hold a ... 11:00 a.m. EDT on Friday, May 15, 2009. Financial,results ... market closes. , Interested parties ...
Cached Medicine News:Health News:Functionalab Launches Exclusively at Henri Bendel Monday, May 11th, 2009 2Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 2Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 3Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 4Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 5Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 6Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 7Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 8Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 9Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 10Health News:Videoconferencing can increase patient access to stroke specialists 2Health News:Videoconferencing can increase patient access to stroke specialists 3Health News:Derma Sciences Announces Date of Its First Quarter 2009 Earnings Release and Conference Call 2Health News:ESA's Corona(R) Family of HPLC Detectors, Including the New Corona ultra(TM), Can Now be Controlled by Waters Empower(R) 2 Chromatography Software 2Health News:Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Third Quarter Earnings Conference Call on Friday, May 15, 2009 at 11:00 a.m. EDT 2
(Date:9/30/2014)... LONDON , Sept. 30, 2014 ... conducting this study is to provide an overview ... global market for protein drugs/therapeutics. The key objective ... direction of protein drugs as an important tool ... report explores present and future strategies within the ...
(Date:9/30/2014)... Mass. , Sept. 30, 2014  Decision Resources Group finds ... Australia , China , ... Korea—will expand at a strong rate through 2023. Dental implant procedure ... and as patient awareness rises. Other key findings from ... dental implant market: , Dental implant penetration: ...
(Date:9/30/2014)... , Sept. 30, 2014   Easy Breathe ... destination , today announced that it now offers the ... AirSense CPAPs are the first sleep apnea therapy devices ... simple and easy to track and share real-time data ... effectiveness of their CPAP therapy.  In addition, the internal ...
Breaking Medicine Technology:Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... BOSTON, Dec. 29, 2011  Solos Endoscopy, Inc. (OTCPK: SNDY) ... continued growth in 2012 through the development and sales ... treatment and management of medical conditions. In 2011, Solos ... approximately $300,000 in debt for the Company. The signed ...
... Dec. 29, 2011 Janssen Research & Development, LLC (JRD) ... Application (sNDA) to the U.S. Food and Drug Administration (FDA) ... an oral anticoagulant, to reduce the risk of (thrombotic) cardiovascular ... The filing is supported by data from the pivotal Phase ...
Cached Medicine Technology:Solos Endoscopy, Inc. is Primed for Growth in 2012 2Solos Endoscopy, Inc. is Primed for Growth in 2012 3Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 2Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 3Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 4Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 5Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 6Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 7Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 8Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 9Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 10Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 11
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: